Am J Transplant, Volume 22, Suppl 3 Archives - Page 24 of 190 - ATC Abstracts

2022 American Transplant Congress
Findings from Pharmacist-Performed Medication Adherence Assessments in Living Donor Kidney Transplant Candidates and Missed Medication Rates Early After Transplant
L. Nguyen¹, R. Samudralwar², A. Forte², G. Malat², C. Christopher¹, J. Rivera¹, T. Ilori¹, X. Liu¹, J. Trofe-Clark²
¹Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute and Pharmacy Dept, Hosp of Univ of Pennsylvania, Philadelphia, PA
*Purpose: Evaluation and monitoring for medication non-adherence (NA) is necessary pre- and post-kidney transplant (KTx) to optimize outcomes. This study aims to describe findings post-implementation…
2022 American Transplant Congress
Successful Implementation of a Rural Appalachian Kidney Transplant Program; One Year Outcomes
F. Afridi¹, B. Gillis¹, R. Lopez¹, D. Kannabhiran¹, V. Chaudhary¹, M. Thornberg¹, R. Zomak¹, K. Meyer¹, C. Newman¹, L. Biondi²
¹Department of Surgery, West Virginia University, Morgantown, WV, ²Department of Surgery, West Virginia University, Morgantown, WV, WV
*Purpose: Kidney transplantation has become the optimal treatment for end stage renal disease (ESRD), allowing dialysis free survival. Despite widespread availability of transplant programs; rural…
2022 American Transplant Congress
Impact of Donor Type, Cold Ischemia Time, and Induction Type on Baseline Donor-Derived Cell-Free DNA in Kidney Transplant Recipients
K. K. Sureshkumar¹, A. Grazier², B. Chopra¹
¹Nephrology, Medicine Institute, Allegheny General Hospital, Pittsburgh, PA, ²Abdominal Transplantation, Allegheny General Hospital, Pittsburgh, PA
*Purpose: Donor derived cell free DNA (dd-cfDNA) is a biomarker useful in predicting acute rejection in kidney allografts. Baseline dd-cfDNA levels are
2022 American Transplant Congress
Six-Month Antibody Kinetics and Durability After Three Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
A. Abedon¹, J. Alejo¹, T. Chiang¹, J. Mitchell¹, J. Kim¹, L. Thomas¹, R. Avery¹, A. Tobian¹, A. Massie¹, M. Levan¹, D. Warren¹, J. Garonzik-Wang², D. Segev¹, W. Werbel¹
¹Johns Hopkins, Baltimore, MD, ²University of Wisconsin, Madison, WI
*Purpose: Some solid-organ transplant recipients (SOTRs) with low or negative antibody levels after a 2-dose mRNA vaccine series against SARS-CoV-2 experience boosting after a third…
2022 American Transplant Congress
Re-Infection with SARS-CoV-2 in Solid-Organ Transplant Recipients: Incidence Density and Convalescent Immunity Prior to Re-Infection
S. Morris¹, S. Anjan¹, S. Pallikkuth², P. Frattaroli³, S. Courel⁴, A. Fernandez⁵, A. Natori⁶, L. Abbo⁷, S. Pahwa², G. Guerra⁸, Y. Natori¹
¹Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ²Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, ³Medicine, Jackson Memorial Hospital, Miami, FL, ⁴University of Miami Miller School of Medicine, Miami, FL, ⁵Infectious Disease Associates of Tampa Bay, Tampa Bay, FL, ⁶Division of Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ⁷Division of Infectious Disease, Department of Medicine, University Of Miami Miller School of Medicine, Miami, FL, ⁸Division of Nephrology, Department of Medicine, University of Miami Jackson Memorial Hospital, Miami, FL
*Purpose: The purpose of this study was to study our cohort of adult solid organ transplant recipients who had been infected with SARS-CoV-2 to describe…
2022 American Transplant Congress
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
M. Nayebpour¹, N. Koizumi¹, J. Melancon²
¹George Mason University, Arlington, VA, ²George Washington University Hospital, Washington, DC
*Purpose: This study aims to validate and apply a personalized optimal dose selection model for Tacrolimus (Tac) for kidney transplant recipients at the George Washington…
2022 American Transplant Congress
Donor/Recipient Variabilities and Dd-cfdna Level
I. Gani¹, L. Mulloy¹, R. Mallavarapu¹, M. Saeed¹, R. Kapoor², A. Mirza¹
¹Augusta University Medical Center, Augusta, GA, ²Southwest Kidney Institute, Phoenix, AZ
*Purpose: Donor-derived cell-free DNA such as AlloSure (CareDx) is used as a non-invasive biomarker for allograft rejection and allograft injury as increased dd-cfDNA is observed…
2022 American Transplant Congress
The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
J. Wu¹, S. Yin¹, F. Zhang¹, L. Wu¹, X. Wang², T. Lin¹
¹urology, west china hospital, Chengdu, China, ²Urology, West China Hospital, Chengdu, China
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients…
2022 American Transplant Congress
Tissue Engineering Scaffolds for Minimally Invasive Immunosurveillance of Acute Cellular Graft Rejection
R. R. Urie¹, D. Farris², A. Morris¹, E. Lombard¹, J. Z. Li³, D. Goldstein², L. Shea¹
¹Biomedical Engineering, University of Michigan, Ann Arbor, MI, ²Internal Medicine, University of Michigan, Ann Arbor, MI, ³Human Genetics, University of Michigan, Ann Arbor, MI
*Purpose: As there is no assay to predict the risk of acute cellular allograft rejection (ACAR), clinicians rely on protocol graft biopsy and aggressive, one-size-fits-all…
2022 American Transplant Congress
Cold Ischemic Time and Kidney Graft Failure; Mediation Through Delayed Graft Function
J. Miller¹, W. Irish², D. Sawinski³, A. Massie⁴, J. Snyder¹
¹Scientific Registry of Transplant Recipients, Minneapolis, MN, ²Department of Surgery, East Carolina University, Greenville, NC, ³Division of Nephrology and Hypertension, Weill Cornell Medical College, New York, NY, ⁴Division of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Delayed graft function (DGF) has been associated with decreased graft survival and prolonged cold ischemia time (CIT) has been proposed as a modifiable DGF…